Market research
AVRO AVROBIO Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 5M
- P/E ratio
- 0.17
- Analyst target
- 2
- Dividend yield
- Not available
- Beta
- 1.22
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US05455M1009
- Market cap
- 5M
- P/E ratio
- 0.17
- Analyst target
- 2
- Dividend yield
- Not available
- Beta
- 1.22
About
About AVROBIO Inc
AVROBIO, Inc., a clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1 and 3; AVR-RD-01, which is in phase 2 clinical trials for the treatment of Fabry disease; and AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the AVRO discussion.
5 years, 4 months ago
AVROBIO, Inc is currently in a long term downtrend where the price is trading 33.1% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
AVROBIO, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 24.1% to $-28M since the same quarter in the previous year.
Finally, its free cash flow fell by 58.0% to $-31M since the same quarter in the previous year.
Based on the above factors, AVROBIO, Inc gets an overall score of 1/5.